Background: The accelerated development of novel cancer therapies necessitates a thorough understanding of the associated cardiotoxicity profiles, due to their significant implications for the long-term health and quality of life of cancer survivors. Objectives: The aim of this study was to determine the association between cardiotoxicity and non-small cell lung cancer (NSCLC) treatments using a hospital medicines usage database in England. Methods: An observational study based on a retrospective design using real-world data from the UK DEFINE database was performed. Monthly secondary data of 40 shortlisted drugs from April 2017 to July 2022 were extracted. Results: The cardiology drug that was associated with most oncology drugs was apixaban. Atezolizumab, bevacizumab, nintedanib, osimertinib, paclitaxel, pembrolizumab, gemcitabine and vincristine were all mostly associated with apixaban, which indicated association with atrial fibrillation. Afatinib, erlotinib and methotrexate were mostly associated with atenolol, hence suggesting the association with ischaemia or hypertension. Docetaxel and epirubicin were associated with verapamil, which indicated association with arrhythmia or hypertension. Conclusions: From the correlation and regression analyses, it can be concluded that hypertension was the most associated cardiovascular disease with the 20 shortlisted oncology drugs. The findings of this study have provided a better understanding of the association between each NSCLC–Cardio drug pair.
背景：新型癌症疗法的加速发展，使得全面了解其相关心脏毒性特征变得至关重要，因为这直接关系到癌症幸存者的长期健康与生活质量。目的：本研究旨在利用英格兰医院用药数据库，探讨非小细胞肺癌（NSCLC）治疗与心脏毒性之间的关联。方法：基于英国DEFINE数据库的真实世界数据，开展了一项回顾性设计的观察性研究。提取了2017年4月至2022年7月期间40种候选药物的月度二级数据。结果：与多数肿瘤药物关联最密切的心脏药物是阿哌沙班。阿特珠单抗、贝伐珠单抗、尼达尼布、奥希替尼、紫杉醇、帕博利珠单抗、吉西他滨和长春新碱均主要与阿哌沙班相关，表明其与心房颤动存在关联。阿法替尼、厄洛替尼和甲氨蝶呤主要与阿替洛尔相关，提示其与缺血或高血压相关。多西他赛和表柔比星与维拉帕米相关，表明其与心律失常或高血压相关。结论：通过相关性与回归分析可得出结论，在20种候选肿瘤药物中，高血压是关联最密切的心血管疾病。本研究结果深化了对各NSCLC-心脏药物组合间关联的理解。
Cancer Therapy-Induced Cardiotoxicity: Results of the Analysis of the UK DEFINE Database
肿瘤(癌症)患者之家